The Mitton-Fry lab expresses its gratitude for research funding from the sources below. We are also thankful for start-up funding from The Ohio State University College of Pharmacy and from the Discovery Themes Initiative.
Ongoing Research Support
Dr. Ralph and Marian Falk Medical Research Trust Transformational Award
Mitton-Fry (PI) with Drs. Lindert, McElroy, Wozniak, and Yalowich as co-investigators
Title: Combating Antibiotic Resistance with Novel Bacterial Topoisomerase Inhibitors
NIH (NIAID) R21 Award
Mitton-Fry (PI) with Drs. Wozniak, and Yalowich as co-investigators
Title: Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Negative Bacteria
NIH (NCI) R01 Award [Nicholas Denko, PI]
Mitton-Fry (co-I)
Title: Overcoming Hypoxic Resistance to Anti-Cancer Therapy
NIH (NIAID) R01 Award [Daniel Wozniak, PI]
Mitton-Fry (co-I)
Title: The Impact of Bacteriophage Therapy on Wound Infection Dynamics
Infectious Diseases Institute at The Ohio State University Seed Grant
Mitton-Fry (PI) with Drs. Wozniak, Wittum, and Parker as co-investigators
Novel Bacterial Topoisomerase Inhibitors for Multidrug-Resistant Gonorrhea Infection
Completed Research Support
Cystic Fibrosis Foundation Pilot and Feasibility Award
Mitton-Fry (PI) with Drs. Wozniak and Yalowich as co-investigators 11/2017-10/2019
Title: Novel Bacterial Type II Topoisomerase Inhibitors to Treat MRSA
Dr. Ralph and Marian Falk Medical Research Trust Catalyst Award
Mitton-Fry (PI) with Drs. Lindert, McElroy, Wozniak, and Yalowich as co-investigators 2/2018-11/2019
Title: Novel Therapies for MRSA and Innovative Methods for Tackling Bacterial Resistance
Cystic Fibrosis Foundation “NIH-Unfunded” Award
Mitton-Fry (PI) with Drs. Wozniak as co-investigator
7/2020-8/2020 (original two-year award relinquished upon start of R21)
Title: Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Negative Bacteria